Cargando…

Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test

INTRODUCTION: Non-Invasive Prenatal Testing (NIPT) for fetal aneuploidies using cell-free DNA (cfDNA) has been widely adopted in clinical practice due to its improved accuracy. A number of NIPT tests have been developed and validated. The purpose of this study is to evaluate the performance of the V...

Descripción completa

Detalles Bibliográficos
Autores principales: Kypri, Elena, Ioannides, Marios, Touvana, Evi, Neophytou, Ioanna, Mina, Petros, Velissariou, Voula, Vittas, Spiros, Santana, Alfredo, Alexidis, Filippos, Tsangaras, Kyriakos, Achilleos, Achilleas, Patsalis, Philippos, Koumbaris, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628499/
https://www.ncbi.nlm.nih.gov/pubmed/31338126
http://dx.doi.org/10.1186/s13039-019-0446-0
_version_ 1783434974389600256
author Kypri, Elena
Ioannides, Marios
Touvana, Evi
Neophytou, Ioanna
Mina, Petros
Velissariou, Voula
Vittas, Spiros
Santana, Alfredo
Alexidis, Filippos
Tsangaras, Kyriakos
Achilleos, Achilleas
Patsalis, Philippos
Koumbaris, George
author_facet Kypri, Elena
Ioannides, Marios
Touvana, Evi
Neophytou, Ioanna
Mina, Petros
Velissariou, Voula
Vittas, Spiros
Santana, Alfredo
Alexidis, Filippos
Tsangaras, Kyriakos
Achilleos, Achilleas
Patsalis, Philippos
Koumbaris, George
author_sort Kypri, Elena
collection PubMed
description INTRODUCTION: Non-Invasive Prenatal Testing (NIPT) for fetal aneuploidies using cell-free DNA (cfDNA) has been widely adopted in clinical practice due to its improved accuracy. A number of NIPT tests have been developed and validated. The purpose of this study is to evaluate the performance of the Veracity NIPT test for sex chromosome aneuploidy (SCA) detection in singleton pregnancies, autosomal aneuploidy detection in twin pregnancies and evaluation of Veracity clinical performance under routine NIPT conditions in a diverse cohort. METHODS: Blinded retrospective study in singleton pregnancies (n = 305); blinded retrospective and prospective study in twin pregnancies (n = 306) and prospective evaluation of clinical performance in singleton and twin pregnancies (n = 10564). RESULTS: Validation study results for the detection of SCAs in singleton pregnancies exhibited 100% sensitivity and specificity and correctly classified 7 (45,X), 4 (47,XXY), 2 (47,XXX) and 1 (47,XYY) cases. Validation study results for autosomal aneuploidy detection in twin pregnancies exhibited 100% sensitivity and specificity and correctly classified 3 trisomy 21, 1 trisomy 18 and 1 trisomy 13 samples. Clinical performance evaluation of Veracity was performed in 10564 pregnancies with median gestational age of 13 weeks, median maternal age 35 years and median gestational weight of 64 kg. Based on confirmation feedback the PPV for trisomies 21, 18 and 13 was estimated at 100% (95% CI, 92–100%), 100% (95% CI, 69–100%) and 71% (95% CI, 29–96%), respectively. Estimated PPV for Monosomy X was 57% (95%CI, 18–90%), while the NPV for SCA detection was estimated at 100% (95% CI, 99.94–100%). CONCLUSION: Veracity NIPT test is based on a very powerful, highly accurate methodology that can be safely applied in the clinical setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13039-019-0446-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6628499
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66284992019-07-23 Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test Kypri, Elena Ioannides, Marios Touvana, Evi Neophytou, Ioanna Mina, Petros Velissariou, Voula Vittas, Spiros Santana, Alfredo Alexidis, Filippos Tsangaras, Kyriakos Achilleos, Achilleas Patsalis, Philippos Koumbaris, George Mol Cytogenet Research INTRODUCTION: Non-Invasive Prenatal Testing (NIPT) for fetal aneuploidies using cell-free DNA (cfDNA) has been widely adopted in clinical practice due to its improved accuracy. A number of NIPT tests have been developed and validated. The purpose of this study is to evaluate the performance of the Veracity NIPT test for sex chromosome aneuploidy (SCA) detection in singleton pregnancies, autosomal aneuploidy detection in twin pregnancies and evaluation of Veracity clinical performance under routine NIPT conditions in a diverse cohort. METHODS: Blinded retrospective study in singleton pregnancies (n = 305); blinded retrospective and prospective study in twin pregnancies (n = 306) and prospective evaluation of clinical performance in singleton and twin pregnancies (n = 10564). RESULTS: Validation study results for the detection of SCAs in singleton pregnancies exhibited 100% sensitivity and specificity and correctly classified 7 (45,X), 4 (47,XXY), 2 (47,XXX) and 1 (47,XYY) cases. Validation study results for autosomal aneuploidy detection in twin pregnancies exhibited 100% sensitivity and specificity and correctly classified 3 trisomy 21, 1 trisomy 18 and 1 trisomy 13 samples. Clinical performance evaluation of Veracity was performed in 10564 pregnancies with median gestational age of 13 weeks, median maternal age 35 years and median gestational weight of 64 kg. Based on confirmation feedback the PPV for trisomies 21, 18 and 13 was estimated at 100% (95% CI, 92–100%), 100% (95% CI, 69–100%) and 71% (95% CI, 29–96%), respectively. Estimated PPV for Monosomy X was 57% (95%CI, 18–90%), while the NPV for SCA detection was estimated at 100% (95% CI, 99.94–100%). CONCLUSION: Veracity NIPT test is based on a very powerful, highly accurate methodology that can be safely applied in the clinical setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13039-019-0446-0) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-15 /pmc/articles/PMC6628499/ /pubmed/31338126 http://dx.doi.org/10.1186/s13039-019-0446-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kypri, Elena
Ioannides, Marios
Touvana, Evi
Neophytou, Ioanna
Mina, Petros
Velissariou, Voula
Vittas, Spiros
Santana, Alfredo
Alexidis, Filippos
Tsangaras, Kyriakos
Achilleos, Achilleas
Patsalis, Philippos
Koumbaris, George
Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test
title Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test
title_full Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test
title_fullStr Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test
title_full_unstemmed Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test
title_short Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test
title_sort non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628499/
https://www.ncbi.nlm.nih.gov/pubmed/31338126
http://dx.doi.org/10.1186/s13039-019-0446-0
work_keys_str_mv AT kyprielena noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT ioannidesmarios noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT touvanaevi noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT neophytouioanna noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT minapetros noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT velissariouvoula noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT vittasspiros noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT santanaalfredo noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT alexidisfilippos noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT tsangaraskyriakos noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT achilleosachilleas noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT patsalisphilippos noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest
AT koumbarisgeorge noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest